United Laboratories International Holdings Ltd

UNJ

Company Profile

  • Business description

    United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.

  • Contact

    No. 6 Fuk Wang Street
    Yuen Long Industrial Estate
    New Territories
    Hong Kong
    HKG

    T: +852 26871033

    http://www.tul.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    18,000

Stocks News & Analysis

stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.
stocks

Revenue growth on track for undervalued ASX healthcare stock

Near-term cost growth does not change our long-term view.
stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,155.8034.000.37%
CAC 408,259.6013.810.17%
DAX 4023,803.953.04-0.01%
Dow JONES (US)47,929.74256.06-0.53%
FTSE 10010,600.532.95-0.03%
HKSE25,893.54141.140.55%
NASDAQ22,885.8063.380.28%
Nikkei 22556,924.111,028.791.84%
NZX 50 Index13,181.4492.37-0.70%
S&P 5006,816.957.71-0.11%
S&P/ASX 2008,960.6036.200.41%
SSE Composite Index3,986.2220.050.51%

Market Movers